预测接受放射治疗骨转移患者的生存:Katagiri评分系统的验证研究
该研究回顾性分析了2004至2013年间接受放射治疗的616例骨转移患者,评估预后因素并验证Katagiri评分系统。多因素分析显示性别、ECOG PS、KPS、原发灶特征、内脏转移、实验室数据和既往化疗与总生存显著相关;Katagiri评分与总生存显著相关(P < 0.001),可帮助选择最佳剂量分割方案。
要点
- 性别、ECOG PS、KPS、原发灶特征、内脏转移、实验室数据和既往化疗是骨转移患者生存的显著预测因素。
- Katagiri评分与总生存显著相关(P < 0.001),评分越高生存率越低。
- Katagiri评分系统可帮助选择骨转移放疗的最佳剂量分割方案。
核心结论
- 性别、ECOG PS、KPS、原发灶特征、内脏转移、实验室数据和既往化疗是骨转移患者生存的显著预测因素。
- Katagiri评分系统与总生存显著相关,可帮助选择最佳剂量分割方案。
研究设计与样本
- 回顾性研究,纳入2004年至2013年间接受放射治疗骨转移的所有患者,共616例。
主要发现
- 616例患者中574例死亡,42例存活;存活者中位随访时间为42个月。
- 单因素分析显示年龄(P = 0.604)和多发骨转移(P = 0.691)与总生存无显著关联。
- 多因素分析显示性别、ECOG PS、KPS、原发灶特征、内脏转移、实验室数据和既往化疗与总生存显著相关。
- 按Katagiri评分分组,3、6、12、24个月生存率分别为:评分0-3组94.4%、77.8%、61.1%;评分4-6组67.7%、48.7%、31.2%;评分7-10组39.1%、22.1%、9.0%(P < 0.001)。
关键数值与推荐
- Katagiri评分0-3分:3、6、12、24个月生存率分别为94.4%、77.8%、61.1%。
- Katagiri评分4-6分:3、6、12、24个月生存率分别为67.7%、48.7%、31.2%。
- Katagiri评分7-10分:3、6、12、24个月生存率分别为39.1%、22.1%、9.0%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The selection of radiation therapy dose fractionation schedules for bone metastases is often based on the estimation of life expectancy. Therefore, accurate prognosis prediction is an important issue. It is reported that the Katagiri scoring system can be used to predict the survival of patients with bone metastases. We aimed to assess prognostic factors and validate the Katagiri scoring system in patients who were treated with radiation therapy for bone metastases. MATERIALS/METHODS: We retrospectively reviewed data of all patients who were treated with radiation therapy for bone metastases between 2004 and 2013. Age, sex, Karnofsky performance status (KPS), Eastern Cooperative Oncology Group performance status (ECOG PS), primary site (lesions and characteristics), visceral metastases, laboratory data, previous chemotherapy, and multiple bone metastases were analyzed for associations with overall survival (OS). Katagiri scores were calculated for each patient and were used to compare OS. RESULTS: Out of the 616 patients included in this analysis, 574 had died and 42 remained alive. The median follow-up time for survivors was 42 months. Univariate analysis revealed that age (P = 0.604) and multiple bone metastases (P = 0.691) were not significantly associated with OS. Multivariate analysis revealed that sex, ECOG PS, KPS, primary characteristics, visceral metastases, laboratory data, and previous chemotherapy were significantly associated with OS. The survival rates at 3, 6, 12, and 24 months, categorized by Katagiri score, were as follows: score 0-3, 94.4, 77.8, and 61.1%, respectively; score 4-6, 67.7, 48.7, and 31.2%, respectively; and score 7-10, 39.1, 22.1, and 9.0%, respectively (P < 0.001). CONCLUSION: Sex, ECOG PS, KPS, primary characteristics, visceral metastases, laboratory data, and previous chemotherapy were significant predictors of survival in patients with bone metastases. The Katagiri scoring system was significantly correlated with OS and can help us select the optimal dose-fractionation.
引用
- Kubota H, Soejima T, Sulaiman NS, et al. Predicting the survival of patients with bone metastases treated with radiation therapy: a validation study of the Katagiri scoring system. Radiat Oncol. 2019. PMID: 30658673. doi:10.1186/s13014-019-1218-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。